Gilead Sciences Management Discusses Q2 2012 Results - Earnings Call ... Seeking Alpha These studies in a placebo-controlled fashion compare GS-1101 added to either Rituximab or to Rituximab with Bendamustine in relapsed refractory CLL patient. My remaining comments will focus on hepatitis C, where progress has been rapid. At the EASL ... |
